Top Industry Leaders in the Scleritis Market
Santen Pharmaceutical Co.: May 2023, Santen launched Siklos (cyclosporine ophthalmic solution) in the US, offering a new topical immunosuppressive option for severe anterior Scleritis.
Alcon Laboratories: March 2023, Alcon received FDA approval for Ximian (dexamethasone intraocular suspension) for the treatment of posterior Scleritis. This injectable steroid provides a targeted option for managing inflammation in the deeper layers of the eye.
Morphic Technologies: July 2023, Morphic Technologies announced positive Phase 2a trial results for its investigational drug MOR103 for the treatment of Scleritis. This novel therapy, if successful in further trials, could offer a non-steroidal and potentially safer alternative for managing Scleritis symptoms.
List of Scleritis Key Companies in the Market
- Amgen
- Amneal Pharmaceuticals LLC
- Baxter International Inc.
- Boehringer Ingelheim
- Fresenius Kabi USA LLC
- Jubilant Cadista Pharmaceuticals Inc.
- Mylan Pharmaceuticals Inc.
- Novartis Pharmaceuticals
- Perrigo Company
- Roxane Laboratories Inc.
- Sandoz Inc.
- Shanghai Henlius Biotech
- Teva Pharmaceuticals USA Inc.
- West-Ward Pharmaceuticals
- Zydus Pharmaceuticals (USA) Inc